Encorafenib in Combination With Binimetinib (Braftovi and Mektovi)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses encorafenib (Braftovi), 75 mg oral capsules in combination with binimetinib (Mektovi), 15 mg oral tablets.
 Indications:
 
 Braftovi (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.
 Mektovi (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.